#1 Clinical Trials Search in Europe

Poractant Alfa

Poractant alfa, also known by its brand name Curosurf, is a natural surfactant used in clinical trials to treat various respiratory conditions, particularly in premature infants with respiratory distress syndrome (RDS). This article examines the use of poractant alfa in different clinical studies, exploring its effectiveness, safety, and potential applications in treating respiratory issues across different age groups.

Table of Contents

What is Poractant Alfa?

Poractant alfa, also known by its brand name Curosurf, is a type of medication called a pulmonary surfactant. It is derived from pig lungs and is used to treat breathing problems in premature infants[1]. Surfactants are substances that reduce surface tension, which is crucial for proper lung function.

What Conditions Does Poractant Alfa Treat?

Poractant alfa is primarily used to treat or prevent a condition called Respiratory Distress Syndrome (RDS) in premature babies. RDS occurs when a baby’s lungs are not fully developed and lack enough natural surfactant, making it difficult for them to breathe[1][2]. In some cases, it has also been studied for use in:

  • Acute Respiratory Distress Syndrome (ARDS) in adults, particularly those with COVID-19[3][4]
  • Pulmonary hemorrhage (bleeding in the lungs) in newborns[5]

How Does Poractant Alfa Work?

When a baby is born prematurely, their lungs may not have produced enough natural surfactant. Poractant alfa works by replacing this missing surfactant. It helps to:

  • Reduce surface tension in the lungs
  • Keep air sacs (alveoli) open
  • Improve oxygen exchange
  • Make breathing easier for the baby[1]
This can lead to better oxygenation and reduced need for mechanical ventilation.

How is Poractant Alfa Administered?

Poractant alfa is typically given to babies soon after birth if they show signs of respiratory distress. It is administered directly into the baby’s lungs through a thin tube inserted into their windpipe (trachea). This process is called endotracheal administration[1]. Some newer methods being studied include:

  • Minimally Invasive Surfactant Therapy (MIST): This involves giving the surfactant through a thin catheter while the baby is breathing on their own with the help of continuous positive airway pressure (CPAP)[2].
  • Nebulization: In some adult studies, researchers are exploring giving surfactant through a nebulizer or during a bronchoscopy (a procedure to look inside the airways)[3].

Effectiveness of Poractant Alfa

Poractant alfa has been shown to be effective in treating RDS in premature infants. Studies have demonstrated that it can:

  • Improve oxygenation
  • Reduce the need for mechanical ventilation
  • Potentially decrease the risk of complications like bronchopulmonary dysplasia (a form of chronic lung disease in infants)[1][6]
Some studies have suggested that poractant alfa may be more effective than other types of surfactants, but more research is needed to confirm this[7][8].

Ongoing Research and Potential New Uses

Researchers are continually studying poractant alfa to find new ways to use it and improve its effectiveness. Some areas of ongoing research include:

  • Using poractant alfa in combination with other medications, such as steroids like budesonide, to potentially enhance its anti-inflammatory effects and further reduce the risk of chronic lung disease[9].
  • Exploring its use in adult patients with ARDS, particularly those with severe COVID-19[3][4].
  • Investigating new methods of administration, such as MIST, which may be less invasive and potentially reduce complications[2][10].

Potential Side Effects and Considerations

While poractant alfa is generally considered safe and effective, like all medications, it can have some side effects. These may include:

  • Temporary changes in heart rate or blood pressure during administration
  • Temporary decrease in oxygen levels
  • In rare cases, pulmonary hemorrhage (bleeding in the lungs)[8]
It’s important to note that the benefits of using poractant alfa in premature infants with RDS generally outweigh the risks. The medication is administered by trained healthcare professionals in a hospital setting where the baby can be closely monitored.

Aspect Details
Primary Use Treatment of Respiratory Distress Syndrome (RDS) in premature infants
Administration Method Intratracheal instillation, often using minimally invasive techniques
Dosage Typically 100-200 mg/kg, with variations based on specific trial protocols
Key Outcomes Measured Oxygenation improvement, need for mechanical ventilation, incidence of bronchopulmonary dysplasia, mortality rates
Emerging Applications Treatment of ARDS in adult COVID-19 patients, management of pulmonary hemorrhage in newborns
Comparative Studies Often compared with other surfactants like beractant or calfactant
Safety Profile Generally well-tolerated, with transient side effects during administration in some cases
Ongoing Research Focus Optimizing administration techniques, exploring use in broader patient populations, long-term outcome studies

FAQ

  • What is poractant alfa used for in clinical trials? Poractant alfa is primarily used in clinical trials to treat respiratory distress syndrome (RDS) in premature infants. It's also being studied for potential use in adults with acute respiratory distress syndrome (ARDS) due to COVID-19.
  • How is poractant alfa administered? Poractant alfa is typically administered intratracheally (directly into the windpipe) through a thin tube. In some trials, it's given using minimally invasive techniques or through a bronchoscope.
  • What are the potential benefits of poractant alfa? Potential benefits include improved oxygenation, reduced need for mechanical ventilation, decreased incidence of bronchopulmonary dysplasia (BPD), and improved survival rates in premature infants with RDS.
  • Are there any side effects associated with poractant alfa? While generally considered safe, some potential side effects may include transient bradycardia and oxygen desaturation during administration. Long-term effects are still being studied in various clinical trials.
  • Is poractant alfa being studied for conditions other than RDS in premature infants? Yes, some clinical trials are exploring the use of poractant alfa in treating adult patients with acute respiratory distress syndrome (ARDS) due to COVID-19, as well as its potential in treating pulmonary hemorrhage in newborns.

Ongoing Clinical Trials on Poractant Alfa

  • Comparing 1-Minute and 5-Minute Poractant Alfa Treatment for Respiratory Distress Syndrome in Very Premature Babies Born Before 28 Weeks

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria

  • Study comparing prophylactic versus selective surfactant (poractant alfa, phospholipid fraction) administration in preterm infants with respiratory distress syndrome aged 25-30 weeks

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany

  • Study on Budesonide and Poractant Alfa for Preventing Lung Disease in Very Preterm Infants

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

Glossary

  • Poractant alfa: A natural surfactant derived from porcine lungs, used to treat respiratory distress syndrome in premature infants by helping to keep the lungs open and facilitating breathing.
  • Respiratory Distress Syndrome (RDS): A breathing disorder that primarily affects premature infants, caused by a lack of surfactant in the lungs, leading to difficulty breathing and the need for respiratory support.
  • Bronchopulmonary Dysplasia (BPD): A chronic lung disease that can develop in premature infants who require prolonged mechanical ventilation or oxygen therapy.
  • Fraction of Inspired Oxygen (FiO2): The concentration of oxygen in the air mixture that a patient is breathing, often used to assess the severity of respiratory issues and the effectiveness of treatments.
  • Minimally Invasive Surfactant Therapy (MIST): A technique for administering surfactant to infants that aims to reduce the need for intubation and mechanical ventilation.
  • Acute Respiratory Distress Syndrome (ARDS): A severe lung condition characterized by rapid onset of widespread inflammation in the lungs, often requiring mechanical ventilation.
  • Nasal Continuous Positive Airway Pressure (NCPAP): A form of non-invasive ventilation that delivers constant air pressure to keep the airways open in spontaneously breathing patients.
  • Pulmonary Hemorrhage: Bleeding into the lungs, a potentially serious complication that can occur in premature infants.
  • Tracheal Aspirate: A sample of fluid collected from the trachea (windpipe) to analyze for various markers of lung function or inflammation.
  • Ventilator-Free Days: A measure used in clinical trials to assess the effectiveness of treatments in reducing the need for mechanical ventilation.

References

  1. https://clinicaltrials.gov/study/NCT02452476
  2. https://clinicaltrials.gov/study/NCT06007547
  3. https://clinicaltrials.gov/study/NCT04384731
  4. https://clinicaltrials.gov/study/NCT04502433
  5. https://clinicaltrials.gov/study/NCT01860014
  6. https://clinicaltrials.gov/study/NCT00501982
  7. https://clinicaltrials.gov/study/NCT01852461
  8. https://clinicaltrials.gov/study/NCT02834624
  9. https://clinicaltrials.gov/study/NCT03521063
  10. https://clinicaltrials.gov/study/NCT00751959